ArticleJournal of cancer research and clinical oncology2022

Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer.

Naoki Shijubou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.